Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.

[1]  J. Kao,et al.  2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.

[2]  J. Kao,et al.  2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.

[3]  K. Krejcy,et al.  Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. , 2020, The Lancet. Haematology.

[4]  S. Martini.  Hepatitis C and liver transplantation. , 2018, Minerva gastroenterologica e dietologica.

[5]  M. Buti,et al.  Natural history and management of hepatitis C: does sex play a role? , 2014, The Journal of infectious diseases.

[6]  Chien-Jen Chen,et al.  Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection. , 2014, Value in health regional issues.

[7]  A. Floreani,et al.  Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response , 2011, European journal of gastroenterology & hepatology.

[8]  A. Francavilla,et al.  Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. , 2011, Gastroenterology.

[9]  B. Bacon,et al.  Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. , 2010, Gastroenterology.

[10]  B. Bacon,et al.  Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. , 2007, The New England journal of medicine.

[11]  Ming‐Lung Yu,et al.  A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C , 2006, Gut.

[12]  P. Marcellin,et al.  Peginterferon-2a and Ribavirin Combination Therapy in Chronic Hepatitis C , 2004, Annals of Internal Medicine.

[13]  L. Seeff,et al.  Natural history of hepatitis C , 1997, Hepatology.

[14]  L. Y. Wang,et al.  The genotypes of hepatitis C virus in patients with chronic hepatitis C virus infection in southern Taiwan. , 1996, The Kaohsiung journal of medical sciences.

[15]  Hour-Young Chen,et al.  Genotype distribution of hepatitis C virus infection in Taiwan , 1994, Journal of medical virology.

[16]  Chien-Jen Chen,et al.  Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. , 1990, The Journal of infectious diseases.

[17]  D. Nelson,et al.  Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. , 2010, Gastroenterology.